Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271587 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TSHRHDAC8TDP1MEN1 | |
| SCHEMBL271586 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TSHRHDAC8TDP1MEN1 | |
| SCHEMBL19844937 | 0.75 | ALDH1A1 (0.44) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL13074567 | 0.73 | NPC1 (0.43) | ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL19844938 | 0.72 | MAPT (0.46) | ALDH1A1TSHRTDP1MEN1KMT2A | |
| SCHEMBL3312607 | 0.71 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1MEN1KMT2A | |
| SCHEMBL28525044 | 0.71 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1MEN1KMT2A | |
| SCHEMBL10030527 | 0.71 | CYP2C9 (0.44) | ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL23691126 | 0.70 | ALDH1A1 (0.55) | ALDH1A1TSHRTDP1MEN1KMT2A | |
| SCHEMBL12677158 | 0.70 | ALDH1A1 (0.55) | ALDH1A1TSHRTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155568-B2 | Bioadhesives | NUTECH VENTURES (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200095270-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | NUTECH VENTURES | 2020-03-26 | — | — | US | disclosed |
| US-20180037598-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155568-B2 | Bioadhesives | EPCAM, VCAM1, SELP | ALDH1A1 337/4885TSHR 4787/4885HDAC8 4016/4885 |
| US-20200095270-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | HLCS, LOX, DCXR | ALDH1A1 247/4885TSHR 4844/4885HDAC8 3579/4885 |
| US-20180037598-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | HLCS, LOX, DCXR | ALDH1A1 247/4885TSHR 4844/4885HDAC8 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.